Eli Lilly, AstraZeneca to co-develop Alzheimer's drug

In This List

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism

9 Dec, 2016 | 17:46

Author Tayyeba Irum
Theme Healthcare & Pharmaceuticals

Eli Lilly & Co. inked an agreement with AstraZeneca PLC to co-develop investigational antibody MEDI1814, a potential disease-modifying treatment for Alzheimer's disease.

MEDI1814 is currently in phase 1 trials. The deal builds on the companies' existing collaboration related to the BACE inhibitor AZD3293 in two phase 3 trials.

Eli Lilly will make an upfront payment of $30 million to AstraZeneca in connection with the agreement. It will also recognize the payment as a charge to earnings in the fourth quarter of 2016.